https://scholars.lib.ntu.edu.tw/handle/123456789/473496
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHUN-JEN LIU | en_US |
dc.contributor.author | PEI-JER CHEN | en_US |
dc.contributor.author | Lai M.-Y. | en_US |
dc.contributor.author | JIA-HORNG KAO | en_US |
dc.contributor.author | YUNG-MING JENG | en_US |
dc.contributor.author | DING-SHINN CHEN | en_US |
dc.creator | Liu C.-J.;Chen P.-J.;Lai M.-Y.;Kao J.-H.;Yung-Ming Jeng;Chen D.-S. | - |
dc.date.accessioned | 2020-03-06T08:25:40Z | - |
dc.date.available | 2020-03-06T08:25:40Z | - |
dc.date.issued | 2003 | - |
dc.identifier.issn | 0270-9139 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984567329&doi=10.1053%2fjhep.2003.50096&partnerID=40&md5=1e4edfd680983a4d60724e952a17effe | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/473496 | - |
dc.description.abstract | Ribavirin and interferon (IFN) are an effective treatment in 30% to 60% of patients with chronic hepatitis C. Whether they are also effective in dually infected patients with hepatitis B and C is unknown. Twenty-four patients with chronic hepatitis seropositive for both hepatitis B surface antigen and antibody to HCV received ribavirin 1,200 mg daily for 6 months, together with 6 million units (MU) IFN-α 2a thrice weekly for 12 weeks and then 3 MU for another 12 weeks. Serum HCV RNA was positive in 21 patients (group I, serum HBV DNA positive in 17 patients) and negative in 3 patients (group II, all HBV DNA positive) by Amplicor (Cobas Amplicor Monitor, Roche Diagnostics, Branchburg, NJ). Serum alanine aminotransferase (ALT), HCV RNA, and hepatitis B virus (HBV) DNA were monitored regularly for 12 months. Another 30 patients with chronic hepatitis C alone receiving the same regimen, served as controls. The serum HCV clearance rate in group I patients (43%) was comparable with that in controls (60%, P = .63) 24 weeks posttreatment. The serum ALT normalization rate in group I and group II patients was 43% and 0%, respectively, 24 weeks posttreatment. After treatment, resurgence of HBV and HCV was encountered in 4 group I patients and 1 group II patient, respectively. In conclusion, in hepatitis B and C dually infected patients, combination of IFN with ribavirin can achieve a sustained HCV clearance rate comparable with hepatitis C alone. In dually infected patients, the treatment may alter the dominant, ruling hepatitis virus. | en_US |
dc.publisher | W.B. Saunders | en_US |
dc.relation.ispartof | Hepatology | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; alpha2a interferon; hepatitis B surface antigen; hepatitis C antibody; ribavirin; virus DNA; virus RNA; adult; alanine aminotransferase blood level; article; chronic hepatitis; clinical article; combination chemotherapy; controlled study; drug efficacy; female; hepatitis B; hepatitis C; Hepatitis C virus; human; male; priority journal; superinfection; treatment outcome | - |
dc.title | Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1053/jhep.2003.50096 | - |
dc.identifier.pmid | 12601355 | - |
dc.identifier.scopus | 2-s2.0-84984567329 | - |
dc.relation.pages | 568-576 | en_US |
dc.relation.journalvolume | 37 | en_US |
dc.relation.journalissue | 3 | en_US |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Pathology | - |
crisitem.author.dept | Pathology-NTUH | - |
crisitem.author.orcid | 0000-0002-6202-0993 | - |
crisitem.author.orcid | 0000-0001-8316-3785 | - |
crisitem.author.orcid | 0000-0002-2442-7952 | - |
crisitem.author.orcid | 0000-0002-3878-4491 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。